Dr. Lam Yuk Keung

Biologic therapies targeting IL-17, IL-23, and IL-4/13 pathways have transformed the treatment of psoriasis and atopic dermatitis. With PASI 90 clearance achievable for most psoriasis patients and significant eczema improvements with dupilumab and JAK inhibitors, the therapeutic goals in dermatology have been fundamentally redefined.